[4] It should not be confused with the strategy of using adenovirus as a viral vector to develop vaccines for other pathogens, or as a general gene carrier.

On 16 March 2011, the U.S. Food and Drug Administration approved an adenovirus vaccine manufactured by Teva Pharmaceuticals under contract to the U.S.

On 24 October 2011, the military services began administering the new adenovirus vaccine to recruits during basic training.

[12] The vaccine is orally administered and consists of live (not attenuated) virus.

The tablets are coated, so that the virus passes the stomach and infects the intestines, where the immune response is raised.